Vasocardin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasocardin

Quick Facts: Vasocardin

Property Description
Active Ingredient Metoprolol
Form Tablet (immediate and extended-release), solution for injection
Pharmacological Class beta-Adrenergic Receptor Antagonist (beta-blocker)
Origin Synthetic compound

What Type of Medicine is Vasocardin and Its Primary Role?

Vasocardin is a prescription-only medicine whose fundamental active ingredient is Metoprolol, an established synthetic compound. Metoprolol belongs to the pharmacological class of beta-adrenergic receptor antagonists, commonly known as a cardioselective beta-blocker. This classification means it preferentially targets the beta1 receptors located mainly in the heart, leading to fewer peripheral effects compared to non-selective agents. Its role in stabilizing the cardiovascular system is a recognized pharmacological application.

The core function of this cardiovascular drug involves its role in managing conditions requiring lower blood pressure and a slower heart rate. This action helps the heart work more efficiently and reduces the strain on the circulatory system. Metoprolol is categorized as an essential medicine within the global healthcare framework.

Composition and Physical Forms of Metoprolol

The active constituent, Metoprolol, is formulated into two key salt forms to govern its release in the body: Metoprolol tartrate and Metoprolol succinate. Vasocardin is therefore available in high-level dosage form(s) such as standard tablets, extended-release tablets, and a sterile solution for injection. The difference in the salts determines the drug's delivery mechanism: Metoprolol tartrate is typically used for immediate action, while Metoprolol succinate is engineered to be extended-release, providing sustained delivery of the Metoprolol base over time. Both forms are administered by the oral route, while the solution is reserved for intravenous use by a healthcare professional.

What is the General Benefit of a Cardioselective beta-Blocker?

The general purpose of a medicine that functions as a selective beta-blocker is to temper the impact of stress hormones like adrenaline on the heart. This physiological action allows the heart to beat more slowly and with less force, promoting cardiac efficiency. By enacting this controlled moderation of cardiac activity, the high-level benefit of Vasocardin is to stabilize the circulatory system, typically utilized in scenarios where a patient's heart requires consistent management of strain and cardiac rhythm.

Regulatory References

  1. Beta Blockers - StatPearls - NCBI Bookshelf
  2. Metoprolol - MedlinePlus Connect
  3. WHO Model Lists of Essential Medicines
  4. Metoprolol on WHO Electronic Essential Medicines List

What side effects are possible with Vasocardin?

Possible Side Effects and Safety Information

The official safety profile for Vasocardin (Metoprolol) classifies adverse reactions based on their expected frequency and the body system affected, strictly following regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reaction is fatigue, which is classified as Very Common in regulatory documents. Common side effects, observed in up to 1 in 10 patients, primarily involve the nervous system (including headache and dizziness) and the cardiovascular system, where a slowing of the heart rate, known as bradycardia, is noted. Other common effects include orthostatic hypotension (low blood pressure upon standing) and gastrointestinal issues such as nausea, diarrhea, or constipation.

Less frequent, Uncommon effects may include depression and abdominal pain. Rare adverse reactions, affecting fewer than 1 in 1,000 patients, include certain skin and subcutaneous tissue disorders such as rash, urticaria, and reversible alopecia. A rare but serious reaction documented in official labeling is the exacerbation of Psoriasis.

Safety Constraints and Considerations

The regulatory label recognizes the potential for bronchospasm as a safety constraint related to the medicine's pharmacological class. Furthermore, official safety notes specify that some adverse effects, such as initial fatigue and dizziness, may be transient and are often noted during the initial phase of treatment. Specific safety consideration is documented as necessary for patients with hepatic impairment (liver dysfunction) due to how the medicine is metabolized. High-level safety restrictions documented in official labels include contraindications for specific severe heart conditions such as cardiogenic shock and high-degree atrioventricular block.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the manifestations and required actions for a Vasocardin (metoprolol) overdose. A suspected overdose requires seeking immediate medical attention due to the risk of severe, life-threatening outcomes.

Documented Overdose Manifestations

System Official Signs and Symptoms
Cardiovascular Severe bradycardia (slow heart rate), hypotension, atrioventricular block, and cardiogenic shock.
Respiratory Bronchospasm and resulting hypoxia.
Central Nervous System Impairment of consciousness or coma.

Required Emergency Actions

The treatment of overdose often requires management in an intensive care setting. Official guidance mandates emergency procedures to counter physiological depression, including the use of glucagon injection, intravenous vasopressor infusion (e.g., dopamine), and dobutamine to manage acute circulatory failure. If cardiac arrest occurs, cardiopulmonary resuscitation (CPR) during several hours may be required. Furthermore, patients with a history of myocardial infarction or heart failure are officially noted as being prone to significant hemodynamic instability during an overdose event.

Therapeutic Uses of Vasocardin

What Vasocardin Treats: Main Uses and Benefits

Vasocardin (Metoprolol) is commonly used to address a range of conditions related to cardiovascular strain and heightened physiological activity. It serves as a component of symptomatic management in several heart and circulatory conditions.

The medicine is relevant for managing conditions that include hypertension (high blood pressure), stable angina pectoris (recurrent chest pain), certain abnormally fast or irregular heart rhythms (arrhythmias), and provides supportive therapy following a myocardial infarction (heart attack).

In these clinical settings, the medication generally assists with maintaining long-term cardiovascular stability and helps ease the overall burden of recurrent physical discomfort. Patients often seek this treatment to help them cope more steadily with difficult episodes.

“This medication is considered relevant for patients with certain types of chronic heart failure, a condition where functional stability becomes affected.”


Quick Fact: Relief for Cardiac Strain

Area of Use Symptom/Condition Eased Benefit
Hypertension Increased physiological stress on arteries Contributes to maintaining functional stability.
Angina Recurrent physical discomfort (chest pain) May assist in managing the symptom frequency.
Post-MI Post-myocardial infarction support Supports patients during chronic symptomatic periods.
Arrhythmia Abnormally fast heart rhythms Helps ease overall symptom load and noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Vasocardin (Metoprolol)

The official eligibility profile for Vasocardin is strictly defined by regulatory authorities, outlining specific patient groups who are permitted or restricted from using the medicine. This section describes population rules based on official product labeling, not clinical advice.


Absolute Contraindications

Vasocardin must not be used by individuals with the following absolute contraindications, as stated in regulatory prescribing information:

  • Severe Bradycardia or a significantly slow heart rate.
  • Second or Third-Degree Atrioventricular (AV) Block.
  • Sick Sinus Syndrome (unless a permanent pacemaker is present).
  • Cardiogenic Shock or Decompensated (Unstable) Heart Failure.
  • Known hypersensitivity to metoprolol or related compounds.

Population and Condition-Specific Eligibility

Population Group Regulatory Eligibility Status
Pediatric Patients Approved for hypertension in those 6 years of age and older. Use is not established for children under 6 or for non-hypertension indications.
Hepatic Impairment Requires use of a lower starting dose due to decreased drug metabolism by the liver.
Pregnancy/Lactation Use during pregnancy is restricted to cases where the benefit justifies potential risk; monitored use is generally recommended during breastfeeding.
Comorbidities Caution is necessary in patients with Diabetes Mellitus (may mask hypoglycemia symptoms) or Peripheral Vascular Disease (may aggravate symptoms).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vasocardin (metoprolol) may interact with various medicines, which can change the effects of either drug. These documented interactions fall into categories based on the mechanism by which they occur.

Interacting Medicine Categories and Implications

Category Relevant Examples Interaction Implication
CYP2D6 Inhibitors Fluoxetine, Paroxetine, Propafenone, Quinidine May significantly increase metoprolol concentration in the body, requiring careful monitoring and potential dose adjustment.
Calcium Channel Blockers Verapamil, Diltiazem Concomitant use may enhance effects on heart rate and contractility (myocardial depression).
Antiarrhythmics Amiodarone, Propafenone May result in additive effects that slow heart rate or depress heart function.
Catecholamine-Depleting Drugs Reserpine May enhance the effect of metoprolol, potentially leading to excessive slowing of the heart rate.
NSAIDs Indomethacin, Celecoxib May reduce the blood pressure-lowering effects of metoprolol.

These interactions are primarily structured by the regulatory documents to account for metabolic interference (inhibition of the CYP2D6 enzyme) and additive pharmacodynamic effects on the cardiovascular system. Due to these potential effects, the use of Verapamil or Diltiazem with metoprolol must be approached with caution, and Propafenone is generally not recommended. The full profile mandates continuous monitoring when combining metoprolol with agents that affect heart function or blood pressure.

Mechanism of Action

Targeted Modulation of Heart Receptor Signaling

Vasocardin (Metoprolol) acts as a highly selective competitive antagonist on the beta1-adrenergic receptors, which are the primary binding sites for catecholamines (stress hormones) in the heart. By blocking these key receptors, the drug directly limits the influence of the Sympathetic Nervous System (SNS) on the cardiac muscle. This action initiates a molecular cascade that leads to reduced heart rate (negative chronotropy) and decreased force of contraction (negative inotropy), thus resulting in reduced cardiac output.

Indirect Suppression of the RAAS Pathway

The drug's mechanism extends beyond the heart to include receptors in the kidney's juxtaglomerular apparatus. Blockade of beta1 receptors in this region suppresses the release of renin, the enzyme that initiates the Renin-Angiotensin-Aldosterone System (RAAS). By modulating this key humoral pathway, Metoprolol indirectly reduces the systemic production of potent vasoconstrictors. This suppression of the RAAS influences peripheral vascular resistance and functions in parallel with the primary cardiac mechanism, influencing systemic hemodynamic parameters.

Dosage and Administration Information

Official Administration Guidelines for Vasocardin (Metoprolol)

Vasocardin is administered through two official routes: primarily oral for long-term maintenance, and via intravenous (IV) injection for initial use in acute, controlled settings, such as following a heart attack. The oral form is available as immediate-release (IR) tablets (Metoprolol Tartrate) and extended-release (ER) tablets or capsules (Metoprolol Succinate), which dictate the required frequency of use.


Dosing Frequency and Schedules

Administration Type Dosing Frequency Pattern High-Level Context
Immediate-Release (IR) Typically twice daily or more in divided doses. Used for indications like angina or following the acute IV phase.
Extended-Release (ER) Administered once daily. Used for chronic management of conditions like hypertension and heart failure.

Key Administration Conditions

The timing of the dose relative to meals depends on the formulation. Immediate-release tablets are typically taken with or immediately following meals to enhance absorption. Conversely, extended-release forms can be taken with or without food. For all ER tablets, standard practice involves swallowing them whole and not crushing or chewing them to preserve the drug's sustained-release properties.

For chronic use, standard adult dosing ranges for hypertension begin from 25 mg to 100 mg once daily for the ER form, with adjustments typically made at weekly or bi-weekly intervals to reach a maintenance dose. If a dose is missed, standard protocols involve taking only the next scheduled dose at the usual time rather than doubling the dose to compensate. Dose adjustments are also explicitly specified for patients with liver impairment, who begin therapy at a lower dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Vasocardin

Evidence for Use in High Blood Pressure (Hypertension)

Research concerning Vasocardin for high blood pressure was evaluated in Randomized Controlled Trials (RCTs) and meta-analyses that examined adult patients. These studies monitored outcomes related to systemic or functional imbalance, specifically looking at changes in blood pressure readings, and tracked the occurrence of major cardiovascular events like heart attacks and stroke.

The findings describe patterns observed in the studies where data show patterns related to measurements of lower blood pressure and lower reported frequencies of major cardiovascular events in treated populations. The general evidence base was assigned an evidence level classification reflecting a High level of consistency in the available findings. Research highlights questions regarding the findings of comparative studies with newer non-beta-blocker agents.


Evidence for Use in Recurrent Chest Pain (Angina Pectoris)

Vasocardin was evaluated in comparative prospective studies and long-term RCTs involving patients whose condition is marked by functional limitations and episodic manifestations of chest pain. Studies monitored outcomes related to physical discomfort, tracking the frequency and severity of chest pain, and measured quality of life. The evidence base for symptomatic outcomes was assigned an evidence level classification reflecting a High level of consistency in the available findings.


Evidence Following a Heart Attack (Post-Myocardial Infarction Support)

The initial research base is built on landmark Randomized Controlled Trials (RCTs), with meta-analyses and current observational patient registries providing additional context. Research examined outcomes related to systemic or functional imbalance, tracking survival, all-cause and cardiovascular mortality, and the rate of recurrence of heart attacks (reinfarction).

Findings describe patterns observed in the studies where lower rates of recurring heart attacks and sudden cardiac death were observed in some studies during the follow-up periods. Research highlights questions regarding the necessary follow-up durations for treatment. Evidence remains limited regarding long-term outcomes beyond a certain point for low-risk populations, and long-term effects are not fully established across all patient profiles.


Evidence for Heart Rhythm Control (Cardiac Arrhythmias)

Vasocardin was studied for conditions characterized by fluctuating or episodic manifestations of heart rhythm issues. Evidence is derived from Systematic Reviews and meta-analyses of randomized trials which research examined outcomes related to systemic imbalance, tracking heart rate control and the rate of arrhythmia recurrence. The research base is often summarized with an evidence level classification ranging from Moderate to High.


What is Still Uncertain or Under Investigation

Research highlights areas of uncertainty related to comparative evidence and the duration of effect. Comparative evidence is lacking to establish patterns against all other classes of cardiovascular medication across every indication. Evidence is limited for long-term use in specific subgroups, and the data are still emerging regarding findings in the context of newer treatment technologies.

Key Studies & References

  1. Beta-blockers are not equivalent to other antihypertensive drugs: a meta-analysis of randomised controlled trials.
  2. Effects of long-term metoprolol administration upon morbidity and mortality in patients with acute myocardial infarction. The Metoprolol in Acute Myocardial Infarction (MIAMI) Trial.

Frequently Asked Questions (FAQ)

Common questions about Vasocardin (FAQ)

Q: What is Vasocardin used for besides just heart issues?

A: According to official product information, the active ingredient metoprolol is approved in some regions for the prophylaxis (prevention) of migraine headaches, in addition to its primary uses for heart conditions like hypertension and angina. Always check the authorized label in your region for the full list of approved uses.

Q: How quickly does Vasocardin start working to lower blood pressure?

A: Regulatory documents indicate that a significant beta-blocking effect, which lowers the heart's workload, occurs within about 1 hour of taking an oral dose. However, the maximum effect of any given dosage level on blood pressure is generally not apparent until after one week of therapy.

Q: What is the average duration before you notice the full effect of Vasocardin?

A: The maximum effect of a specific dose on blood pressure is typically seen after approximately one week of continuous therapy. This timeframe helps guide healthcare providers when considering a dosage adjustment.

Q: Do you have to take Vasocardin forever once you start it?

A: The duration of treatment is determined by a healthcare professional based on your underlying condition. If treatment discontinuation is necessary, official information states that the dosage should typically be gradually reduced over a period of 1 to 2 weeks, rather than stopping abruptly.

Q: Does alcohol interact with Vasocardin?

A: The product label advises that alcohol may need to be avoided or limited, as it can potentially increase side effects like drowsiness and dizziness and may have an additive effect in lowering blood pressure. Additionally, for some extended-release formulations, alcohol can cause the medicine to release too quickly.

Q: What are the signs of an allergic reaction to Vasocardin?

A: The product is contraindicated (should not be used) in people with a known hypersensitivity to metoprolol or related components. Although rare, anaphylactic reactions (severe allergic reactions) have been reported in post-marketing experience. If signs of a severe reaction occur, immediate professional medical evaluation is necessary.

Q: Does Vasocardin cause weight gain or loss?

A: While not listed as a common side effect in clinical trials, weight gain has been reported in post-marketing experience for the extended-release formulation. The management of cardiovascular health often involves lifestyle changes, such as diet and exercise, which should be discussed with a healthcare provider.

Q: Can taking Vasocardin cause problems with sexual function?

A: Disturbances in sexual function have been reported as a rare adverse reaction in post-marketing experience with the active ingredient.

Q: Why is Vasocardin sometimes prescribed for people without high blood pressure?

A: The active ingredient metoprolol is approved for multiple heart-related conditions beyond just hypertension. These include the treatment of angina pectoris (chest pain), managing heart failure, and to improve survival after a heart attack.

Q: Does Vasocardin impact blood sugar levels?

A: Official information states that Vasocardin may mask certain signs of acute hypoglycemia (low blood sugar), such as a rapid heart rate. This aspect means that patients with Diabetes Mellitus should ensure their healthcare provider is aware of this possibility, as monitoring requirements may change.

Q: Is it better to take Vasocardin in the morning or at night?

A: Extended-release forms are typically taken once daily and should be taken at the same time each day. Because of the possibility of dizziness, your healthcare provider may recommend a specific time of day for administration. The extended-release form should generally be taken at the same time each day.

Q: Does Vasocardin have a withdrawal period if stopped suddenly?

A: Official warnings state that abrupt cessation of therapy can be associated with serious consequences, including the worsening of angina and an increased risk of heart attack. If discontinuation is deemed necessary by a healthcare professional, the dosage is usually gradually reduced over a period of time to manage the risk.

Q: Why is it important to tell my dentist I am taking Vasocardin?

A: Since Vasocardin affects your heart rate and blood pressure, its use is relevant to procedures involving surgery or certain types of anesthetics. Your dentist or oral surgeon needs this information to ensure any planned procedures are performed safely.

Q: How do I know if the Vasocardin is actually working?

A: For managing high blood pressure, effectiveness is primarily measured by blood pressure reduction. Your healthcare provider will monitor your blood pressure and heart rate to ensure the medication is achieving its intended therapeutic effect.

Q: What should I do if my blood pressure still seems high while on Vasocardin?

A: Official dosing guidelines state that dosages are typically adjusted at weekly or longer intervals until the best response is reached. If a patient has concerns that their blood pressure remains high, their next step is to communicate with their healthcare provider, who can evaluate the dosage or consider combination therapy.

Q: Can Vasocardin make your heart race or palpitate?

A: The main function of Vasocardin is to slow the heart rate (bradycardia). However, a rapid heart rate (tachycardia) or palpitations may occur as part of a withdrawal syndrome if the medicine is stopped abruptly or if a dose is missed.

Q: Are there generic versions of Vasocardin available?

A: Yes, the active ingredient in Vasocardin, Metoprolol, is widely recognized by health authorities and is available as a generic medication.

Q: Are there any studies comparing Vasocardin's effectiveness to lifestyle changes?

A: The FDA label indicates that the complete treatment program for conditions like hypertension includes a combination of medication with diet, exercise, and weight control. While the drug’s effectiveness is established, most regulatory documents do not explicitly detail head-to-head trials against lifestyle changes alone.

Q: Is a slight headache a common side effect when starting Vasocardin?

A: Headache is listed in official documents as a Common side effect, experienced by up to 1 in 10 patients. Some side effects, like initial fatigue and dizziness, are often transient and may lessen during the initial phase of treatment.

Q: Does Vasocardin affect cholesterol levels?

A: Official information indicates that beta-blockers, the class of drugs Vasocardin belongs to, may alter serum lipid profiles. This includes reports of changes in certain cholesterol and triglyceride levels. Patients with pre-existing high cholesterol may require closer monitoring by their healthcare provider.

Q: Can taking Vasocardin affect kidney function?

A: While the drug is known to indirectly suppress the Renin-Angiotensin-Aldosterone System (RAAS) which involves the kidneys, the official safety profile does not list specific adverse effects on kidney (renal) function as a common side effect.

Q: Can Vasocardin interact badly with common pain relievers like ibuprofen?

A: Official interaction information states that NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effects of metoprolol. It is important to inform a healthcare provider of all medicines being taken.

Q: Why did my doctor switch me from a different medication to Vasocardin?

A: Vasocardin is a cardioselective beta-blocker, meaning it primarily targets the heart. The decision to use this medicine over others is a professional choice based on individual patient requirements and medical history.

Q: Can I take Vasocardin if I already have low blood pressure sometimes?

A: Vasocardin works to lower blood pressure, and low blood pressure upon standing (orthostatic hypotension) is a common side effect. Individuals with pre-existing low blood pressure should ensure their healthcare provider is aware of this condition, as it may influence the decision to start treatment.

Q: Is Vasocardin safe to use before an upcoming surgery?

A: Official product information is silent on detailed patient guidance for elective surgery preparation. This information needs to be discussed with the surgical and prescribing healthcare team regarding the need to continue or temporarily adjust the medication before any planned surgical procedure.

Q: Does Vasocardin cause swelling in the ankles or feet?

A: Swelling in the ankles or feet (edema) is not listed as a common adverse reaction in the official regulatory documents for Vasocardin. The side effect profile primarily highlights issues like fatigue, dizziness, and slow heart rate.

Q: Is Vasocardin okay to take if I have liver problems?

A: Yes, official eligibility guidelines specify that Vasocardin requires a lower starting dose for patients with hepatic impairment (liver problems). This is because the drug is metabolized (processed) by the liver.

Q: Is it safe to take Vasocardin with an aspirin a day?

A: Official interaction documents do not specifically list low-dose aspirin as a major interaction requiring dose adjustment. However, it is important that the healthcare provider is aware of all concomitant medications, including daily low-dose aspirin.

How should Vasocardin be stored and disposed of?

Vasocardin (Metoprolol Tartrate) tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F). Brief excursions are generally permitted between 15°C and 30°C.

Key Storage Conditions

Condition Recommendation
Temperature Below 25°C (77°F)
Protection Keep containers tightly closed and protect from moisture and light.
Safety Store securely, out of the reach of children and pets.

To dispose of unused or expired Vasocardin, do not flush it down a toilet or pour it down a drain unless specifically instructed by an authorized source. Instead, utilize a drug take-back program offered by a local pharmacy or law enforcement agency. If a take-back program is unavailable, mix the medication with an unappealing substance, such as dirt or used coffee grounds, place it in a sealed bag or container, and discard it in your household trash. This method helps prevent accidental ingestion by others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasocardin found in:

A-Z Index: